Darden Restaurants reported increased profit and sales in its fiscal fourth quarter, with net earnings of $404.9 million, or $3.51 per share, up from $303.8 million, or $2.58 per share, a year earlier. Sales rose 14% to $3.72 billion, largely driven by strong comparable sales from its LongHorn Steakhouse brand.

Darden Restaurants Inc. shares dropped after Olive Garden's same-store sales missed expectations, overshadowing the company's better-than-expected overall earnings. Olive Garden's 2.4% same-store sales growth fell short of the 3.4% estimate, indicating that promotions and smaller portions were insufficient to counteract pressure on lower and middle-income consumers. Despite this, Darden reported adjusted earnings of $3.66 per share, surpassing analyst estimates.

DARDEN RESTAURANTS ($DRI) reported its Q4 2026 earnings, missing both earnings per share and revenue estimates. The company reported earnings of $3.66 per share against an estimate of $3.67, and revenue of $3.718 billion against an estimate of $3.765 billion. The article also details significant insider selling activity, hedge fund movements, congressional stock trades, and recent analyst price targets for $DRI.

Teledyne Technologies' FLIR Defense unit has secured a $28.8 million contract from U.S. Customs and Border Protection for its Enhanced Mobile Surveillance Capability-Lite program. The 24-month contract involves delivering advanced Lightweight Vehicle Surveillance Systems to be primarily deployed along the Southwest border. These systems, utilizing radar and electro-optical/infrared cameras, will help Border Patrol agents detect and track individuals, vehicles, and animals, with initial deliveries expected in Q3 2026.

SealSQ and WiseKey, through their special-purpose vehicle Quantisimo, are collaborating with GigCapital8 to establish a Nasdaq-listed quantum technology platform. The initial valuation is $575 million, with plans to grow it to $2 billion through the acquisition of five quantum companies. This initiative follows a U.S. executive order to strengthen the quantum industry, aiming to provide investors direct exposure to the burgeoning quantum technology market.

Firefighters have finally extinguished an eight-day blaze at a 500,000-square-foot cold food storage warehouse in Boyle Heights, marking the end of a long battle that prompted air quality advisories and shelter-in-place orders. The next phase involves the removal of debris and millions of pounds of food, with authorities investigating the fire's cause, which Lineage, the tenant-operator, suggests originated on the roof during tests conducted by solar array owner Altus Power. Los Angeles Mayor Karen Bass has thanked firefighters and vowed to hold those responsible accountable for the incident, which incurred approximately $3 million in LAFD-related costs for taxpayers.

Barclays has increased its price target for Delta Air Lines (DAL) to $105 from $85, while reiterating an Overweight rating on the stock. This adjustment reflects a more optimistic outlook for the airline, following similar target increases from other analysts like Evercore ISI and Jefferies. The market closed with Delta Air Lines (DAL) at 90.65 USD, showing a pre-market gain of +4.53% at 91.02 USD.

CNSide Diagnostics, a subsidiary of Plus Therapeutics Inc., has signed a national agreement with Elevance Health Inc. to provide its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay. This deal, effective May 1, 2026, expands coverage to approximately 45.4 million people in the U.S., bringing CNSide's total contracted coverage for its CSF TCE assay to 126 million people. The agreement builds on Plus Therapeutics' recent positive financial developments and strategic partnerships.

KeyCorp raised its FY2026 EPS estimate for Worthington Steel (NYSE:WS) from $2.15 to $2.16, maintaining an "Overweight" rating and a $46 price target. The firm also initiated a FY2027 EPS projection of $2.50. This comes after Worthington Steel reported strong Q1 results, with an EPS of $0.74 topping estimates, though revenue of $929.2 million fell short of expectations.

Plus Therapeutics, through its wholly-owned subsidiary CNSide Diagnostics, LLC, has signed a national coverage agreement with Elevance Health for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This agreement covers approximately 45.4 million people in the U.S., increasing CNSide's total contracted coverage to 126 million. The CNSide® assay aids in the rapid diagnosis, treatment monitoring, and guidance for patients with leptomeningeal metastases, demonstrating high sensitivity and specificity in over 11,000 tests performed since 2020.